CLEARWATER, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- MedWell Ai, Inc, (OTCQB:MWAI) ("Company") is a portfolio company, specializing in AI-driven solutions for B2B markets in pharmaceuticals, healthcare, and wellness, is pleased to confirm the filing, after the market close, of its Quarterly Report (Form 10-Q), for the financial period, ending on December 31, 2025. The Company reported $548,315 in Revenue for its fiscal second quarter of 2025. This performance was result of a successful strategic s ...

Core Insights - Femto Technologies Inc. has launched Sensera, a tech-enabled intimacy device aimed at delivering personalized wellness experiences, now available for purchase at a retail price of $299 [1] - Sensera features Femto's proprietary Smart Release System (SRS), which adapts to user preferences and refines its responses over time through continuous use [2][3] - The device utilizes real-time physiological metrics to provide adaptive performance tailored to individual users, supported by a dedicated iOS app for customized programs [3] Company Overview - Femto Technologies Inc. is a publicly traded company focused on advancements in the femtech and wellness industries, aiming to create a holistic ecosystem of smart devices and integrated products [5] - The company emphasizes the integration of data science, user experience, and health-focused design in its product offerings [5] - Sensera has been recognized as a CES Innovation Awards 2025 Honoree in the Artificial Intelligence category, highlighting its innovative approach to personal wellness [4]

Core Viewpoint - Pegasus Mercantile Inc. is currently under a Failure-to-File Cease Trade Order (FFCTO) due to its inability to file annual financial statements by the deadline, resulting in a suspension of trading on the Canadian Securities Exchange [1]. Group 1: Default Status Update - The British Columbia Securities Commission (BCSC) issued the FFCTO on February 4, 2026, because the company failed to file its annual financial statements and management's discussion and analysis (MD&A) for the year ended September 30, 2025 by January 28, 2026 [1]. - The FFCTO will remain in effect until the company fulfills all annual financial filing requirements and receives a revocation order from the BCSC [1]. Group 2: Management Actions - The company's management and audit committee are actively working with auditors to complete the necessary documents for the annual financial filings [2]. - The company plans to issue weekly default status reports and confirms that there is no undisclosed material information regarding its affairs [2]. Group 3: Company Overview - Pegasus Mercantile is a prospect generator that supports high-growth companies with financial, operational, and management assistance [3]. - The company is diversifying its focus into sectors such as global wellness, psychedelics, mycology, hemp and CBD, and healthcare-related clinical studies and trials [3].

RT fitz ⨀ (@FitzYap)Industries & grifts that will prob be durable in a post AGI world:-wellness & life extension-entertainment-experiences/travel-handmade goods-art-food & bev-sports & rec lessons, especially those embedded in nature (skiing, surfing, scuba, sailing etc)-niche services for post-economic cohort (film/photog, make edits for them. Aura farming as a service)-drugs & conciousness expansion (think aesop coded ayahuasca retreat)-architecture, interior design, landscapinga lot of left leaning peopl ...

Core Viewpoint - Sportstech Brands Holding GmbH disputes claims made by Interactive Strength Inc. regarding legal obligations and asserts that these claims are factually and legally incorrect [1][2][3] Legal Position - Sportstech has conducted a comprehensive legal review and believes that the loan agreements from January 27, 2025, and May 22, 2025, are void under German law [2][4] - The company has initiated legal steps to clarify its position under German law and has not been served with any lawsuits from TRNR in Germany [3][4] Claims and Negotiations - Sportstech denies the existence of the claims asserted by TRNR in the amounts alleged and maintains that any documents related to a potential acquisition were not binding [5][6] - The company is open to constructive discussions with TRNR regarding any legally valid obligations and is willing to negotiate a settlement [7][9] Operational Status - Despite the ongoing legal dispute, Sportstech continues its business operations without restrictions and is pursuing its strategic growth trajectory [9][10] - The company is confident that an agreement will be reached, albeit for a significantly lower amount than previously claimed [9] Market Position - Sportstech Brands Holding GmbH is recognized as an internationally active company in the home fitness, wellness, and lifestyle products sector, holding a strong market position in Europe [11]

Core Viewpoint - MEDIROM Healthcare Technologies Inc. has entered into a Master Service Agreement with Tools for Humanity and the World Foundation to support the adoption of World ID by installing Orb devices across 3,000 locations in Japan [2][3]. Group 1: Company Overview - MEDIROM is engaged in diversified healthcare businesses and operates approximately 300 wellness salons under the "Re.Ra.Ku" brand [10]. - The company has expanded into HealthTech since 2015, offering on-demand training apps and manufacturing health-related devices like the "MOTHER Bracelet" [10]. Group 2: Partnership and Deployment Strategy - The deployment of Orbs will begin with over 150 wellness centers operated by MEDIROM, with plans to expand to approximately 300 centers across the Re.Ra.Ku Group [4]. - MEDIROM aims to collaborate with member stores of the Japan Relaxation Industry Association and other retail providers to achieve nationwide coverage of approximately 3,000 locations [4][5]. Group 3: Technology and Product Details - The Orb device allows individuals to verify their uniqueness and create a secure World ID on their phones, facilitating the adoption of World ID [3]. - Tools for Humanity, co-founded by Sam Altman and Alex Blania, is responsible for the development of the World Project and operates the World App [8].

Investment Rating - The report indicates a positive outlook for the AI-driven wellness industry, emphasizing that AI is becoming the core operating layer rather than an add-on feature [6][15]. Core Insights - The wellness industry is transitioning to adaptive systems that leverage AI to enhance user engagement and outcomes, driven by advancements in behavioral and biometric modeling, multi-step orchestration, and real-time computing [3][6]. - By 2026, over 60% of digital wellness interactions will be managed by AI systems, significantly improving engagement and retention metrics [8][15]. - The focus is shifting from mere engagement metrics to measurable health outcomes, with platforms competing on improvements in fitness, sleep, and metabolic health [11][12]. Summary by Sections Executive Summary - AI is central to transforming wellness platforms from episodic experiences to adaptive systems that respond in real-time [3][4]. Key Signals - AI will drive over 60% of digital wellness interactions by 2026, with personalized onboarding increasing early engagement by 22-40% [8]. Predictions for 2026 - Agentic wellness copilots will manage most member interactions, allowing human coaches to focus on complex cases [9][10]. - Wellness brands will prioritize measurable outcomes over engagement metrics [11]. - Hyper-personalized, self-tuning programs will become the standard expectation for users [13][14]. Technology Foundations - The report outlines a five-layer AI stack that enables continuous adaptation in wellness platforms, moving beyond static programs [68]. - Multi-agent orchestration systems will coordinate various AI agents across the member journey, enhancing personalization and effectiveness [69]. ROI Mandate - The performance of AI-driven wellness systems will be evaluated based on measurable, repeatable outcomes, focusing on activation, retention, and operational efficiency [86][90]. - Illustrative performance metrics indicate significant improvements in engagement and retention rates due to AI orchestration [91][97]. What's Next: 2027-2028 Outlook - Future wellness platforms will evolve into systems that continuously adapt to user behavior, integrating predictive modeling and preventive wellness strategies [101][109].

Core Viewpoint - Unilever PLC (NYSE:UL) is facing challenges in its stock performance and market confidence, with recent downgrades from analysts indicating concerns over valuation and earnings growth potential [2][3]. Group 1: Analyst Ratings and Price Targets - BNP Paribas downgraded Unilever PLC from Outperform to Neutral with a price target of $71, citing that valuations in the consumer staples sector are expected to remain "cheap" [2]. - Jefferies maintained an Underperform rating but raised its price target for Unilever from 4,000 GBp to 4,100 GBp, highlighting challenges in price and operating margins that limit earnings growth [2]. Group 2: Financial Performance and Market Concerns - Unilever's stock is down by 1.65% year-to-date as of January 9, 2026, indicating a negative market sentiment [3]. - Jefferies noted that volume and mix are expected to be approximately 2% in the fourth-quarter results, with concerns about declining U.S. growth contributions affecting market confidence in the first half of 2026 [2].

Financial Data and Key Metrics Changes - The company reported a record Q2 net revenue of $218 million, with an adjusted EBITDA of $8.4 million and a reported EPS loss of $0.02, reflecting a significant improvement in performance metrics [4][22]. - The net loss for the quarter was $43.5 million, a 49% improvement year-over-year compared to $85.3 million, with cash flow used in operations reduced to $8.5 million from $40.7 million last year [26][27]. Business Line Data and Key Metrics Changes - Cannabis net revenue increased to $67.5 million, driven by a 36% increase in international cannabis revenue and a 6% increase in Canadian adult-use cannabis [22][23]. - Beverage revenue totaled $50.1 million, impacted by headwinds in the craft beer segment, while distribution revenue grew by 26% year-over-year to $85.3 million [11][23]. - Wellness revenue remained flat year-over-year at $14.6 million, with challenges in the club retail channel being addressed [24]. Market Data and Key Metrics Changes - The international cannabis business saw a 51% sequential growth, reaching $20 million, marking one of the strongest quarters to date despite ongoing regulatory challenges [9][10]. - In Canada, the adult-use medical sales channel net of excise tax grew to $46 million, with recreational cannabis sales increasing by 6% [12][22]. Company Strategy and Development Direction - The company aims to leverage its strong balance sheet and cash position to capitalize on strategic opportunities in a rapidly evolving regulatory environment, particularly in the U.S. cannabis market [5][28]. - Tilray is focused on expanding its pharmacy reach in Germany and tripling its medical cannabis distribution footprint in fiscal 2026 [10][11]. - The company emphasizes the importance of modernizing Canadian cannabis regulations to maintain its competitive edge in the global market [14][15]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory for the second half of fiscal 2026 and beyond, citing a diversified platform and improving fundamentals [21][28]. - The company is prepared for potential regulatory changes in the U.S. and anticipates that cannabis rescheduling will lead to a federally compliant medical cannabis framework [7][8]. Other Important Information - The company operates more than 40 brands in over 20 countries and is a leader in various segments, including cannabis, craft beer, and wellness products [5][6]. - The company has a strong cash position of approximately $292 million, providing flexibility for strategic investments [5][27]. Q&A Session Summary Question: What can the industry do to improve the regulatory outcome regarding the intoxicating hemp ban? - Management is working with legislators to extend the deadline or modify regulations to allow for a regulated amount of milligrams to be sold nationally [33][34]. Question: Can you quantify how much supply was held back from the Canadian market? - Approximately $5 million worth of supply was held back, which will be redeployed into higher-margin international markets [37][38]. Question: How much of the Canadian adult-use cannabis growth was volume versus price mix? - The growth was primarily driven by demand and new distribution, with a slight market share gain despite challenges [45][46]. Question: What are the expectations for growth within the Canadian market? - Management anticipates mid- to high single-digit growth, focusing on premium products and new product launches [57][58]. Question: Can you provide more color on the CC Pharma business and its distribution reach? - The company aims to triple its distribution reach and is focused on leveraging its sales organization to sell more medical cannabis in Germany [67][68].

Core Insights - Tilray Brands, Inc. reported a record net revenue of $218 million for the second fiscal quarter ended November 30, 2025, reflecting a 3% increase compared to the previous year [3][5] - The company is well-positioned for growth in the U.S. medical cannabis market, anticipating federal rescheduling to enhance research and patient access [3][5] - Tilray's financial position remains strong with $292 million in cash and marketable securities, and a net cash position of approximately $30 million [2][4][6] Financial Performance - Net revenue increased by 3% to $217.5 million from $211.0 million year-over-year [5][28] - Cannabis net revenue rose by 3% to $67.5 million, driven by a 36% increase in international cannabis revenue and a 6% increase in Canadian adult-use cannabis [5][32] - Gross profit decreased to $57.5 million from $61.2 million, with a gross margin of 26% compared to 29% in the prior year [5][28] Segment Performance - Beverage net revenue was $50.1 million, down from $63.1 million, with a gross margin of 31% compared to 40% [5][32] - Distribution net revenue reached a record $85.3 million, up from $67.6 million, with a gross margin of 13% [5][32] - Wellness segment revenue remained flat at $14.6 million, with a slight increase in gross profit [5][32] Loss and Adjustments - The net loss improved to $(43.5) million from $(85.3) million, with net loss per share improving to $(0.41) from $(0.99) [5][28] - Adjusted EBITDA was $8.4 million, slightly down from $9.0 million [5][28] - Adjusted net loss and adjusted net loss per share improved to $(2.0) million and $(0.02), respectively [5][28] Cash Flow and Balance Sheet - Cash used in operations improved by $32.2 million to $(8.5) million from $(40.7) million [4][30] - The cash and marketable securities balance grew to $291.6 million, providing flexibility for strategic opportunities [4][6] - Total outstanding debt was reduced by $4.2 million, strengthening the balance sheet [4][6]